# Eos BioInnovation

> Eos BioInnovation is a VC fund in Cambridge backing Biotechnology, Medical and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 5
- Last investment: May 2026
- Lead investor: 40%
- Last updated: Aug 2026
- Website: https://eosbioinnovation.com/

Eos BioInnovation is an investment firm launching and building start-ups in the area of regenerative medicine and encompasses therapies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |
| Health Care | 1 | 20% |
| Life Science | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 60% |
| Series A | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 1 | 20% |
| Switzerland | 1 | 20% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Autoimmunity BioSolutions | Autoimmunity BioSolutions is working on a next-generation immuno-corrective therapy that restores normal immune function in a genetically defined subgroup of autoimmune patients, where the autoimmune pathology is driven by an SNP. | $1M | Seed | May 06, 2026 |  |
| TECregen | TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses. | $12.5M | Seed | Jan 08, 2026 |  |
| Autoimmunity BioSolutions | Autoimmunity BioSolutions is working on a next-generation immuno-corrective therapy that restores normal immune function in a genetically defined subgroup of autoimmune patients, where the autoimmune pathology is driven by an SNP. | $2M | Seed | Nov 21, 2024 |  |
| Axonis Therapeutics | Axonis translates breakthrough regeneration research to groundbreaking paralysis therapy, to transform the lives of spinal cord injury patients. | $115M | Series A | Oct 30, 2024 |  |
| HDAX Therapeutics | HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. | $3.2M | Seed | Sep 05, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [FACIT](https://shizune.co/investors/profile/facit-prospects-oncology-fund) — VC Fund, 2 deals together
- [Independent Capital Management, Inc.](https://shizune.co/investors/profile/independent-capital-management-inc) — VC Fund, 2 deals together
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 1 deal together
- [BoxOne Ventures](https://shizune.co/investors/profile/boxone-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does Eos BioInnovation invest in?

Eos BioInnovation invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eos BioInnovation last invest?

The most recent investment recorded for Eos BioInnovation closed in May 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co